An International Phase II Trial of Single-Agent Nivolumab for Hodgkin Lymphoma Relapsed or Refractory After Autologous Stem Cell Transplant
10:52 Share

This podcast describes the extended follow-up of the large International phase II CheckMate 205 study of single-agent nivolumab for patients with relapsed/refractory classical Hodgkin lymphoma after failure from autologous stem cell transplant.

Read the related article on JCO.org).